SLAM
ALXN

Swiss Life Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Swiss Life Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-22,510
Closed -$1.49M – 583
2021
Q2 		$1.49M Sell
22,510
-27,979
-55% -$4.8M 0.02% 450
2021
Q1 		$7.72M Buy
50,489
+26,313
+109% +$4.07M 0.11% 227
2020
Q4 		$3.78M Buy
24,176
+22,241
+1,149% +$2.86M 0.06% 344
2020
Q3 		$221K Hold
1,935
– – ﹤0.01% 465
2020
Q2 		$217K Buy
+1,935
New +$205K ﹤0.01% 495
2020
Q1 		– Sell
-2,123
Closed -$230K – 527
2019
Q4 		$230K Hold
2,123
– – ﹤0.01% 493
2019
Q3 		$208K Hold
2,123
– – ﹤0.01% 504
2019
Q2 		$277K Hold
2,123
– – ﹤0.01% 515
2019
Q1 		$287K Buy
+2,123
New +$264K ﹤0.01% 473
2018
Q4 		– Sell
-2,123
Closed -$295K – 505
2018
Q3 		$295K Buy
2,123
+363
+21% +$45.5K ﹤0.01% 496
2018
Q2 		$219K Buy
+1,760
New +$206K ﹤0.01% 505
2018
Q1 		– Sell
-1,760
Closed -$211K – 537
2017
Q4 		$211K Buy
+1,760
New +$214K ﹤0.01% 474
2016
Q2 		– Sell
-38,338
Closed -$5.34M – 394
2016
Q1 		$5.34M Hold
38,338
– – 0.23% 97
2015
Q4 		$7.31M Hold
38,338
– – 0.33% 81
2015
Q3 		$6M Buy
38,338
+5,240
+16% +$956K 0.29% 85
2015
Q2 		$5.98M Buy
33,098
+2,524
+8% +$436K 0.21% 84
2015
Q1 		$5.3M Buy
+30,574
New +$5.53M 0.21% 89

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Swiss Life Asset Management's ALXN Position: Q3 2021 in Review

Swiss Life Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 22,510 shares — an estimated $1.49M sold.

Swiss Life Asset Management first reported a position in ALXN in Q1 2015 and held it in 17 quarters. The position peaked at $7.72M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Swiss Life Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Swiss Life Asset Management sold 22,510 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.49M.
  • Swiss Life Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 17 quarters.
  • Swiss Life Asset Management's Alexion Pharmaceuticals position peaked at $7.72M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Swiss Life Asset Management's 13F filing for Q3 2021, filed 29 Dec 2025.